News & Updates
Filter by Specialty:
AChEIs and memantine cost-effective, offer improvements in AD
09 May 2022
byNatalia Reoutova
A systematic review and meta-analysis of Alzheimer’s disease (AD) therapies’ cost-effectiveness carried out by researchers from the Chinese University of Hong Kong (CUHK) identifies acetylcholinesterase inhibitors (AChEIs) and memantine as cost-effective and offering improvements in dementia-related symptoms.
AChEIs and memantine cost-effective, offer improvements in AD
09 May 2022Platelet function a potential biomarker of Alzheimer’s disease
07 May 2022
A higher platelet response in middle-aged individuals who are free of antiplatelet therapy carries an increased risk of dementia in late life, according to a cohort study with 20 years of follow up.
Platelet function a potential biomarker of Alzheimer’s disease
07 May 2022Physical activity associated with intact cognition after mild or moderate stroke
07 May 2022
byNatalia Reoutova
A Swedish register-based study finds that patients who engage in light or moderate physical activity are more likely to retain their cognitive function after a mild or moderate stroke vs inactive counterparts.